Quick Answer
Esperion Therapeutics, Inc. reported Diluted EPS of $0.11 per share (loss) for fiscal year 2025.
Esperion Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.11 | +60.7% |
| 2024 | -$0.28 | +86.2% |
| 2023 | -$2.03 | +42.3% |
| 2022 | -$3.52 | +62.2% |
| 2021 | -$9.31 | -78.0% |
| 2020 | -$5.23 | -45.7% |
| 2019 | -$3.59 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | -6.7% | -166.7% |
| June 30, 2025 | -$0.06 | +81.8% | +71.4% |
| March 31, 2025 | -$0.21 | -161.8% | -40.0% |
| September 30, 2024 | -$0.15 | +59.5% | +54.5% |
| June 30, 2024 | -$0.33 | +28.3% | -197.1% |
| March 31, 2024 | $0.34 | +143.0% | +191.9% |
| September 30, 2023 | -$0.37 | +54.3% | +19.6% |
| June 30, 2023 | -$0.46 | +56.2% | +41.8% |
- Esperion Therapeutics, Inc. showed an increase of +60.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Esperion Therapeutics, Inc.’s diluted eps has grown by 96.9% (from $3.59 per share (loss) to $0.11 per share (loss)).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: